Microfluidics: The next wave of disruptive technology in radiochemistry?

Microfluidic technology may offer faster and more controlled ways to produce radiotracers for medical imaging, including studies into Parkinson's disease, thanks to a first of its kind approach in the Southern Hemisphere at ANSTO.

Positron Emission Tomography (PET) is the leading technique capable of investigating a range of , including drug distribution and organ molecular functioning, after the injection of a radiopharmaceutical into the body.

Due to the short half-lives of these radionuclides, there's a growing demand for new PET tracer molecules that must be prepared rapidly and used to diagnose a range of conditions, including brain or or cancer.

Microfluidic devices could be the key

To explain how these devices work is simple. They consist of miniature plumbing that can deal with the behaviour, control and manipulation of fluids at a microlitre scale. What they offer though in terms of outcomes could one day be to radiochemistry what smartphones have been to telecommunications, leading to PET radiotracer production being no longer a niche field, but achievable by a wider field of scientists. This in turn, will provide better biological impacts and improved health outcomes for patients.

Research has already demonstrated its benefits with 18F-altanserin, a PET radiotracer which images the in the brain. It can be produced in 60-70 per cent radiochemical yield in 20 minutes under conventional (vessel-type) chemistry; microfluidic technology allows a similar yield to be produced in 47 seconds using 85 per cent less chemical mass.

This technique has major potential, but is not new. The field has been around since the 1980s and used in the development of inkjet printheads, and then translated to DNA chips, lab-on-a-chip technology, micro-propulsion, and micro-thermal technologies. It was only as recent as 2004 though, when the merits of its use in PET radiochemistry were realised.

ANSTO researchers Dr Giancarlo Pascali and Dr Lidia Matesic are now studying its applications for improved research outcomes in the study of neurological diseases, including Alzheimer's and Parkinson's using the microfluidic NanoTek platform.

The device is a modular synthesis system and the only one of its kind in Australia, with the ability to undertake both microscale and macroscale synthesis of both PET and SPECT imaging probes using a variety of isotopes.

Dr Pascali, a world-renowned expert in microfluidic radiochemistry, is leading the study and believes the technique could be a game-changer in the field of both basic research and commercial tracer production.

"The traditional vessel-based approach suffers from limitations concerning flexibility, reagent mass needed, hardware requirements, large number of connections and valves, repetitive cleaning procedures and overall big footprint to be shielded from radiation. For these reasons, several research groups have started to investigate the application of the fast growing field of microfluidic chemistry to radiosynthetic procedures.

After the first report in 2004, many scientific papers have been published and demonstrated the potential for increased process yields, reduced reagent use, improved flexibility and general ease of setup," he said.

The radiochemists, who are based at ANSTO's Camperdown campus in the LifeSciences labs, are in the initial stages of their work, but are already seeing the benefits of their research.

It's hoped in time that the research will lead to pre-clinical trials and then to human studies.

add to favorites email to friend print save as pdf

Related Stories

SPECT/MR molecular imaging system makes its debut

Jun 11, 2013

The Society of Nuclear Medicine and Molecular Imaging's 2013 Annual Meetingmarks the unveiling of the successful application of a new preclinical hybrid molecular imaging system—single photon emission tomography and magnetic ...

PET/MR effective for imaging recurrent prostate cancer

Jun 11, 2013

When prostate cancer makes a comeback, it becomes increasingly important to have exceptional imaging available to find all possible regions where cancer has spread to other parts of the body, or metastasized, in order to ...

Recommended for you

What are the chances that your dad isn't your dad?

Apr 16, 2014

How confident are you that the man you call dad is really your biological father? If you believe some of the most commonly-quoted figures, you could be forgiven for not being very confident at all. But how ...

New technology that is revealing the science of chewing

Apr 15, 2014

CSIRO's 3D mastication modelling, demonstrated for the first time in Melbourne today, is starting to provide researchers with new understanding of how to reduce salt, sugar and fat in food products, as well ...

After skin cancer, removable model replaces real ear

Apr 11, 2014

(HealthDay)—During his 10-year struggle with basal cell carcinoma, Henry Fiorentini emerged minus his right ear, and minus the hearing that goes with it. The good news: Today, the 56-year-old IT programmer ...

Italy scraps ban on donor-assisted reproduction

Apr 09, 2014

Italy's Constitutional Court on Wednesday struck down a Catholic Church-backed ban against assisted reproduction with sperm or egg donors that has forced thousands of sterile couples to seek help abroad.

User comments